Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The British Association of Dermatologists' Biologic Interventions Register (BADBIR) in patients with severe psoriasis

Next Previous
Trial Profile

The British Association of Dermatologists' Biologic Interventions Register (BADBIR) in patients with severe psoriasis

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary) ; Etanercept (Primary) ; Guselkumab (Primary) ; Secukinumab (Primary) ; Ustekinumab (Primary) ; Acitretin; Ciclosporin; Fumaric acid; Hydroxycarbamide; Infliximab; Ixekizumab; Methotrexate; Psoralens
  • Indications Plaque psoriasis; Psoriatic arthritis
  • Focus Therapeutic Use
  • Acronyms BADBIR; BADBIR

Most Recent Events

  • 28 Aug 2022 Results (n= 6,607 ) assessing PsA, nail involvement, previous biologic exposure, and ethnicity as factors that have a differential effect on drug survival dependent on the choice of biologic therapy, presented at the 38th International Conference on Pharmacoepidemiology and Therapeutic Risk Management
  • 05 Jun 2021 Data from this study was used to evaluate the baseline characteristics and comorbidities in PsO patients with and without a PsA diagnosis presented at the 22nd Annual Congress of the European League Against Rheumatism.
  • 02 Dec 2020 Results (n=1231) assessing the comparative effectiveness of ustekinumab and secukinumab in patients with psoriasis, and the relative effectiveness estimate of the CLEAR trial, published in the JAMA Dermatology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top